Tempus AI (TEM) and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced a new collaboration. The two companies ...
It was a big week for AI-focused startups with Abridge and OpenEvidence both receiving sizable funding rounds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback